PCN85 Economic Assessment of the Oncotype DX Breast Cancer Assay  by Escalona, S. et al.
utilities for pazopanib and placebo were from PALETTE. Lacking a connected evi-
dence network, estimates of relative effectiveness for trabectedin and ifosfamide
were from an unadjusted indirect treatment comparison vs. pazopanib. Costs were
from NHS reference costs and other published sources. RESULTS: Compared with
placebo, pazopanib is estimated to increase QALYs by 0.130 and costs by £8,072; the
incremental cost effectiveness ratio (ICER) for pazopanib vs. placebo is estimated to
be £63k/QALY gained. For most parameters, the ICER changed 30% with /50%
changes in the parameter value. Compared with trabectedin and ifosfamide, pazo-
panib provides equal or more QALYs at a lower cost. CONCLUSIONS: From a UK
health care system perspective, pazopanib may not be cost-effective vs. placebo in
patients with advanced/metastatic STS based on criteria typically used to evaluate
therapies in the UK. Pazopanib may be cost-effective vs. trabectedin and ifosf-
amide, although there is substantial uncertainty associated with these compari-
sons.
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OBJECTIVES: Eurtact trial was the first randomized phase III trial evaluating effi-
cacy and safety of erlotinib vs chemotherapy in the first-line treatment of EGFR
mut Caucasian patients. This trial showed an increase in the median PFS of 4,5
months with erlotinib vs chemotherapy. Based on this study, we aimed to assess
the cost-effectiveness of erlotinib versus platinum based chemotherapy in the
first-line treatment of advanced NSCLC patients with activating EGFR mutations.
METHODS: A health economic cost-effectiveness analysis was developed incorpo-
rating a Markov model simulating the evolution of a cohort of advanced NSCLC
patients with activating EGFR mutations. Three health states were included: Pro-
gression Free Survival (PFS), Progression and Death. The time horizon was 7 years.
Outcomes were life years gained (LYG). Resource utilization related to each health
state was estimated by a Spanish Expert Panel. Cost were expressed in € 2012 and
include drug and administration costs, and drug-related adverse events manage-
ment cost. This analysis was performed taking into account the Spanish National
Health System’s perspective. Patient data on progression-free and overall survival
were obtained from the EURTAC study. Probabilistic sensitivity analyses were con-
ducted to incorporate parameter uncertainties.RESULTS: Erlotinib treated patients
achieved a mean of 2.161 LYG compared to 1.555 LYG in patients receiving chemo-
therapy. Total mean treatment cost with erlotinib and chemotherapy was €22,458
and €5,335 respectively. The incremental cost-effectiveness ratio (ICER) per LYG
was €28,261. Since erlotinib treatment is prolonged until disease progression and
chemotherapy is stopped at 4 cycles, treatment duration is one of the cost-driver of
the model. CONCLUSIONS: Erlotinib treatment of NSCLC patients with activating
EGFR mutations is associated with an increased life expectancy and is a cost-
effective therapeutic option in Spain.
PCN83
COST EFFECTIVENESS ANALYSIS IN THE VENETO REGION OF CABAZITAXEL
VERSUS MITOXANTRONE IN PATIENTS WITH METASTATIC HORMONE
REFRACTORY PROSTATE CANCER, PREVIOUSLY TREATED WITH A DOCETAXEL
CONTAINING REGIMEN
Maran PR1, Aiello A1, Magrì MR1, Alberti C1, Visentin E1, Venturini F2, Scroccaro G3
1UVEF Regional Drug Coordination Centre, Verona, Italy, Italy, 2Azienda Ospedaliera
Universitaria Integrata di Verona, Verona, Italy, 3Regione del Veneto, Venezia, Italy
OBJECTIVES: Hormone refractory prostate cancer has generally poor prognosis
with an expected median survival of approximately 12 months. Cabazitaxel is an
antineoplastic agent, recommended by NCCN guidelines in metastatic, hormone-
resistant patients, after docetaxel therapy. Available alternatives are: mitoxan-
trone, a second docetaxel-containing regimen and other rescue chemotherapies.
Although in Italy an official cost-effectiveness threshold value is not identified, the
Italian Association of Health Economics (AIES) identifies a range from € 25.000 to €
40.000/QALY or LYG. The objective of the study is to evaluate the cost-effectiveness
of cabazitaxel versus mitoxantrone in the Regional Health Service (RHS).
METHODS: Survival data from the TROPIC trial were used to calculate the Incre-
mental cost-effectiveness Ratio (ICER). The maximum hospital wholesale price
allowable for Cabazitaxel and regional tender price for mitoxantrone were used to
calculate costs of treatment (e.g. 6 cycles every 3 weeks). The perspective was
RHS’s. It was decided to develop a conservative analysis and to quantify only the
cost of drugs, as other direct costs (i.e. staff, premedication, managing adverse
events) were not quantifiable or highly variable. The cost of drug administration
was not considered, since it was the same for both drugs. RESULTS: Therapy with
cabazitaxel versus mitoxantrone leads to an increase of the survival ( 0.20/years)
and an increase of costs ( €18.785). The ICER is € 93.925/LYG. CONCLUSIONS: The
estimated ICER is similar to what is shown in the more complete analysis of the
National Institute for Health and Clinical Excellence and the Scottish Medicines
Consortium. Moreover, the analysis was conservative because cabazitaxel showed
more adverse events than mitoxantrone. If quantified, the ICER would have been
higher. The Pharmacy and Therapeutic Committee of the Veneto Region expressed
a negative opinion to the inclusion of the drug in the Regional Drug Hospital For-
mulary.
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OBJECTIVES: The purpose of this study was to explore the cost-effectiveness of
abiraterone acetate (abiraterone) vs. cabazitaxel in metastatic castration-resistant
prostate cancer (mCRPC) patients who progressed after docetaxel from the Greek
health care perspective. METHODS: As no head-to-head trial data were available
for abiraterone versus cabazitaxel, an indirect cost-effectiveness model was devel-
oped using clinical data (progression free survival (PFS), overall survival (OS), ad-
verse events (AEs)) from the pivotal Phase 3 clinical trials COU-AA-301 (abiraterone)
and TROPIC (cabazitaxel). The basic assumption in the model was that both com-
parator arms in the trials were ‘palliative’ and therefore equivalent. Resource use,
particularly for the management of AEs, was estimated based on data from Alex-
andra University Hospital in Athens. For validation purposes, a secondary analysis
was conducted using UK resource use data. Both analyses used local 2012 costs,
undiscounted. Costs of hospitalisation, day hospital visits, drug administration
and laboratory tests were taken from officially published public tariffs. Drug acqui-
sition costs came from the latest Price Bulletins. Since abiraterone and cabazitaxel
are not yet marketed in Greece, respective prices were estimated based on avail-
able EU prices in April 2012. Calculations were based on the median treatment
duration for each agent. RESULTS: Total treatment cost was lower for abiraterone
(€25.847) compared to cabazitaxel (€26.648). Higher drug acquisition costs for abi-
raterone (€24.899 vs. €23.886 for cabazitaxel) were offset by lower administration
costs (€844 vs. €2.292) and lower AE management costs (€104 vs. €470). The total
treatment costs of abiraterone were €12.924 and €5.619 per incremental month of
PFS and OS compared to palliative care, respectively; treatment costs for cabazi-
taxel were €19.034 and €11.103 per additional month of PFS and OS against pallia-
tive care, respectively. Results were validated by the secondary analysis.
CONCLUSIONS: Abiraterone appears to be a potentially cost-effective option com-
pared with cabazitaxel in the Greek health care setting.
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OBJECTIVES: To perform an analysis, from a public financing viewpoint, of the
economic impact and efficiency of the Oncotype DX (ODX) assay as a guide to
providing chemotherapy to women with early breast cancer compared to guiding
this decision using the Adjuvant! Online (AO) prognostic index.METHODS:Markov
model was constructed to assess three alternatives: provision of chemotherapy to
women with a high risk recurrence score (RS) (i.e., 30) with ODX, to women with
an intermediate/high risk score (RS 18) and to those as indicated by the AO. For
the base case, a price of €3200 was set for ODX plus €236.12 for treatment with
tamoxifen for 6 months, plus €3490.50 for six cycles of chemotherapy. RESULTS:
Mean cost associated with AO to guide the provision of chemotherapy was €8994.02
per patient, with ODX RS 30 as a guide was €11,521.56, and for RS 18 it was
€12,070.03. The incremental cost effectiveness ratio for ODX RS 30 compared to
AO was €9659.28 per QALY; for ODX RS 18 was €7105.80. When treatment was
guided by AO, a mean of 16.80 QALYs were obtained per patient, ODX was associ-
ated with a mean 17.06 QALY with an RS of 30 and 17.13 QALY per with an RS of
18. In probablistic sensitivity analysis, assuming a willingness to pay of €10,000/
QALY, providing chemotherapy to patients with an ODX RS of18 became the best
alternative. Probability of this being the best choice was 60% for a willingness to pay
of €20,000 /QALY and 70% for €30,000 /QALY. CONCLUSIONS: Compared to guiding
the provision of chemotherapy with AO, the ODX would appear to be cost-effective.
In the Spanish setting, for a willingness to pay €30,000/QALY, the best option would
appear to be to prescribe chemotherapy for patients with ODX RS of 18.
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OBJECTIVES: To estimate the cost-effectiveness of once-daily abiraterone acetate
(AA) plus prednisolone for the treatment of advanced metastatic castration-resis-
tant prostate cancer (mCRPC) after failure of taxane-based chemotherapy such as
docetaxel, under the Brazilian Private Health System perspective. METHODS: A
cost-effectiveness analysis was developed based in a Markov model to simulate the
disease progression and patient mortality. A systematic revision of the literature
was developed over the efficacy and safety of the use of AA and cabazitaxel (C),
both combined with prednisolone (P), in patients diagnosed with advanced mCRPC.
Efficacy data is informed by the Phase III trials (C  P versus mitoxantrone (M)  P
and AA  P versus P). Data is combined and adjusted via a mixed treatment com-
parison network meta-analysis to determine the relative efficacy of each compar-
ator front a controlled therapy used as efficacy reference for the clinical tests (HR
for overall survival (OS): CP vs M  0.703 (IC95%: 0.59-0.83); AA  P vs P  0.649
(IC95%: 0.543-0.768)). It was assumed that M  P is equal to P alone. The costs and
consequences of the disease treatment were computed for each treatment alter-
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